Open Access

Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy

  • Authors:
    • Toshiaki Takahashi
    • Nobuyuki Yamamoto
    • Tomohide Tamura
    • Hideo Kunitoh
    • Yutaka Nishiwaki
    • Shunichi Negoro
  • View Affiliations

  • Published online on: August 29, 2011     https://doi.org/10.3892/ol.2011.398
  • Pages: 1033-1040
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative erythropoiesis-stimulating agent with unique erythropoietin receptor activity and a prolonged half-life. C.E.R.A. is currently in development for the correction of anemia and stable hemoglobin (Hb) control at extended administration intervals in patients with cancer who are receiving chemotherapy. The purpose of this pharmacological study was to evaluate the pharmacokinetic (PK), pharmacodynamic (PD) and safety profiles of C.E.R.A. administered subcutaneously once every 3 weeks (Q3W) in lung cancer patients with anemia induced by chemotherapy. This open-label, multicenter study recruited 46 patients. Entry Hb levels were not more than 11.0 g/dl. Five dose levels of C.E.R.A. (2.1, 4.2, 6.3, 9 and 12 µg/kg) were tested in sequential cohorts of 8-11 patients for 12 weeks. The mean values for C.E.R.A half-life ranged from 143 to 247 h. The maximum serum concentration (Cmax) following the first administration of C.E.R.A. increased in proportion to the dose. The increase of Hb levels occurred in a dose-dependent manner. No serious adverse events reported as being related to C.E.R.A. were observed during the study period. Thrombovascular events were not observed in any patient. Anti-C.E.R.A antibodies were not detected in any patient. Thus, this pharmacological study confirmed the long half-life of C.E.R.A., thereby supporting subcutaneous administration of C.E.R.A. at the Q3W interval. PK and PD parameters demonstrated dose-proportionality over the range of doses tested in this study. Additionally, C.E.R.A. was generally well tolerated.
View Figures
View References

Related Articles

Journal Cover

November-December 2011
Volume 2 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takahashi T, Yamamoto N, Tamura T, Kunitoh H, Nishiwaki Y and Negoro S: Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy. Oncol Lett 2: 1033-1040, 2011
APA
Takahashi, T., Yamamoto, N., Tamura, T., Kunitoh, H., Nishiwaki, Y., & Negoro, S. (2011). Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy. Oncology Letters, 2, 1033-1040. https://doi.org/10.3892/ol.2011.398
MLA
Takahashi, T., Yamamoto, N., Tamura, T., Kunitoh, H., Nishiwaki, Y., Negoro, S."Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy". Oncology Letters 2.6 (2011): 1033-1040.
Chicago
Takahashi, T., Yamamoto, N., Tamura, T., Kunitoh, H., Nishiwaki, Y., Negoro, S."Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy". Oncology Letters 2, no. 6 (2011): 1033-1040. https://doi.org/10.3892/ol.2011.398